Embree Financial Group Has $568,000 Stock Position in Novo Nordisk A/S $NVO

Key Points

• Embree Financial Group reduced its holdings in Novo Nordisk A/S by 35.9%, now owning 8,231 shares valued at $568,000.
• In the latest earnings report, Novo Nordisk A/S beat analysts' expectations with an earnings per share of $0.97, compared to the forecast of $0.93.
• Novo Nordisk A/S recently cut its dividend, with a semi-annual payment issued, representing a dividend yield of 240.0%.

Embree Financial Group lowered its holdings in shares of Novo Nordisk A/S (NYSE:NVO - Free Report) by 35.9% in the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 8,231 shares of the company's stock after selling 4,618 shares during the period. Embree Financial Group's holdings in Novo Nordisk A/S were worth $568,000 at the end of the most recent quarter.

Several other large investors have also added to or reduced their stakes in the business. First Hawaiian Bank grew its stake in Novo Nordisk A/S by 0.6% during the first quarter. First Hawaiian Bank now owns 22,401 shares of the company's stock worth $1,556,000 after purchasing an additional 142 shares during the period. Anchor Investment Management LLC grew its stake in Novo Nordisk A/S by 1.1% during the first quarter. Anchor Investment Management LLC now owns 13,597 shares of the company's stock worth $944,000 after purchasing an additional 150 shares during the period. Xponance Inc. grew its stake in Novo Nordisk A/S by 5.0% during the first quarter. Xponance Inc. now owns 3,314 shares of the company's stock worth $230,000 after purchasing an additional 158 shares during the period. Foster Dykema Cabot & Partners LLC grew its stake in Novo Nordisk A/S by 3.8% during the first quarter. Foster Dykema Cabot & Partners LLC now owns 4,526 shares of the company's stock worth $319,000 after purchasing an additional 166 shares during the period. Finally, 180 Wealth Advisors LLC grew its stake in Novo Nordisk A/S by 3.6% during the first quarter. 180 Wealth Advisors LLC now owns 5,014 shares of the company's stock worth $348,000 after purchasing an additional 173 shares during the period. Institutional investors and hedge funds own 11.54% of the company's stock.

Novo Nordisk A/S Stock Down 4.5%

NVO stock opened at $56.07 on Friday. Novo Nordisk A/S has a twelve month low of $45.05 and a twelve month high of $125.62. The company has a quick ratio of 0.56, a current ratio of 0.78 and a debt-to-equity ratio of 0.52. The stock's 50 day moving average is $56.20 and its 200-day moving average is $64.68. The firm has a market capitalization of $250.35 billion, a PE ratio of 15.40, a P/E/G ratio of 2.22 and a beta of 0.66.

Novo Nordisk A/S (NYSE:NVO - Get Free Report) last posted its earnings results on Wednesday, August 6th. The company reported $0.97 earnings per share for the quarter, beating analysts' consensus estimates of $0.93 by $0.04. Novo Nordisk A/S had a return on equity of 78.64% and a net margin of 35.60%.The company had revenue of $11.69 billion for the quarter, compared to analyst estimates of $77.51 billion. Sell-side analysts expect that Novo Nordisk A/S will post 3.84 EPS for the current fiscal year.

Novo Nordisk A/S Cuts Dividend

The business also recently announced a semi-annual dividend, which was paid on Tuesday, August 26th. Stockholders of record on Monday, August 18th were issued a $0.4119 dividend. This represents a dividend yield of 240.0%. The ex-dividend date was Monday, August 18th. Novo Nordisk A/S's dividend payout ratio (DPR) is currently 22.53%.

Analyst Ratings Changes

Several equities research analysts recently commented on the company. Wall Street Zen cut Novo Nordisk A/S from a "buy" rating to a "hold" rating in a research note on Saturday, August 2nd. Berenberg Bank upgraded Novo Nordisk A/S from a "hold" rating to a "buy" rating in a report on Wednesday, September 17th. TD Cowen cut their price target on Novo Nordisk A/S from $105.00 to $70.00 and set a "buy" rating on the stock in a report on Tuesday, August 19th. Rothschild Redb upgraded Novo Nordisk A/S from a "hold" rating to a "strong-buy" rating in a report on Tuesday, September 16th. Finally, Rothschild & Co Redburn upgraded Novo Nordisk A/S from a "neutral" rating to a "buy" rating in a report on Tuesday, September 16th. One research analyst has rated the stock with a Strong Buy rating, six have given a Buy rating, eleven have issued a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of "Hold" and an average price target of $81.00.

About Novo Nordisk A/S

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.

Want to see what other hedge funds are holding NVO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Novo Nordisk A/S (NYSE:NVO - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.